Organisation paid for research Program year 2025 Source: CMS Open Payments

Arlington Dermatology

Neither a doctor nor a teaching hospital

Research payments

$1,303,020

254 payments

Through program year 2025, Arlington Dermatology is reported as receiving $1,303,020 in research payments, across 254 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$63,865	16
2024	Research	$81,467	42
2023	Research	$131,132	13
2022	Research	$125,922	40
2021	Research	$397,096	76
2020	Research	$502,596	66
2019	Research	$943	1

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $1,001,189 156 payments
E.R. Squibb & Sons, L.L.C. $97,569 3 payments
Incyte Corporation $62,543 68 payments
Teva Pharmaceuticals USA, Inc. $55,460 7 payments
Almirall LLC $51,213 8 payments
Arcutis Biotherapeutics, Inc. $29,627 5 payments
Galderma Research & Development, LLC $4,478 6 payments
Bausch Health US, LLC $943 1 payment

Studies the money was for Research payments · program years 2019–2025

M15-997 $226,371 37 payments
M19-164 $165,927 14 payments
A multicenter, open Label study to assess the safety and efficacy of risankizumab for maintenance in moderate to severe plaque type psoriasis (LIMMITLESS) $159,528 30 payments
A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUTING IMPACT OF DEUCRAVACITINIB ON QoL, EFFICACY AND SAFETY IN PATIENTS WITH PLAQUE PSORIASIS AND IMPAIRED HEALTH-RELATED QUALITY OF LIFE $95,169 2 payments
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy $79,974 16 payments
A Phase 3b, Multicenter, Interventional, Open-label Study of Adult Subjects with Moderate to Severe Plaque Psoriasis who have a Suboptimal Response to Secukinumab or Ixekizumab and are Switched to Risankizumab $73,593 7 payments
M16-833 $73,312 8 payments
A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis $55,988 37 payments
Study Comparing Tapinarof Cream 1% To VTAMA (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis $55,460 7 payments
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa $52,835 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.